Loading the next story…
Trump Plans Removal of FDA Commissioner Marty Makary — Nerve Wires | Nerve News
Skip to content
NERVE.NEWS
TodayStoriesWinners & LosersForecasts
Auto
Set the atmosphere

Scenery follows the section you’re exploring.

Subscribe

Explore Nerve

Desks & tools

The briefingStory hubsForecastsPrimersLiveblogWinners & LosersSearchSaved storiesDataWires

Categories

All categories →PoliticsEconomyForeign AffairsDefense & SecurityImmigration & BorderMedia & TechCulture & SocietyLaw & JusticeEducationDaily RoundupNewsroom
Subscribe to Nerve
Higher contrast, reduced visual effects, and simplified popups. Your choice is saved for this browser.
TodayBriefingSaved
Back to the briefingBriefingNERVE.NEWS

The Nerve Briefing

Power, culture, technology, and the world taking shape — when we publish. Subscribe →

NERVE.NEWS

A clear view of a changing world. Reporting and ideas with an American perspective.

Coverage

  • Economy
  • Foreign Affairs
  • Politics
  • Media & Tech
  • Culture & Society
  • Opinion
  • All sections
  • Wires
  • Forecasts

Resources

  • Primers
  • Policy Papers
  • Newsletter
  • RSS — All articles
  • RSS — Wires
  • Data
  • The briefing

Publication

  • Subscribe
  • Winners & Losers
  • Editorial Policy
  • About
© 2026 Nerve News. All rights reserved.
EthicsPrivacyAbout
Home/Wires
WireMay 9, 2026 at 12:31 AM

Trump Plans Removal of FDA Commissioner Marty Makary

1 min left
0%

Reading controls

Reading Progress0%
Time remaining1 min
Total reading time1 min
Focus modeDims surrounding paragraphs

Editorial note

Comments

Previous

U.S. Forces Strike Iranian Oil Tankers Amid Ceasefire Tensions

Next

April Jobs Report Shows Strong Gains Amid Economic Uncertainty

President Trump has approved a plan to remove Food and Drug Administration (FDA) Commissioner Marty Makary, though sources emphasize the decision is not yet finalized. The potential ousting follows a year marked by significant challenges and controversies at the agency.

Internal Turmoil and Controversies

Makary's tenure has been fraught with disputes over vaccine approvals, gene therapy decisions, and regulatory oversight of abortion pills and vaping products. Additionally, internal personnel conflicts and budget cuts have further destabilized the FDA, raising questions about its leadership and direction.

The administration has not yet determined who would serve as acting director following Makary's departure.

Implications for American Health Policy

The FDA plays a critical role in safeguarding public health and ensuring the safety of food, drugs, and medical devices. A leadership change could signal a shift in regulatory priorities, particularly in areas such as drug approvals and pandemic response. The move comes at a time when the agency faces heightened scrutiny over its handling of COVID-19 vaccines and treatments.

As the Trump administration weighs its next steps, the focus remains on restoring stability and confidence in the FDA's ability to protect American consumers and workers.